Q-omics provides the consensus-scored CCNJP2 profile across patient tissues and cancer cell-line models. CCNJP2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CCNJP2 is differentially expressed in 3, with the highest sampling consensus in BLCA. Additionally, CCNJP2 RNA expression shows 6,533 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and BLCA as cancer lineages where CCNJP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNJP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNJP2 survival associations across molecular data types. CCNJP2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNJP2 RNA expression–survival associations across cancer types. High CCNJP2 expression shows unfavorable associations in SKCM, THCA, TGCT and LIHC, but favorable associations in STAD and HNSC. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for CCNJP2 RNA expression.
This table summarizes CCNJP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCNJP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNJP2 shows lower tumor expression in LUSC and CHOL and higher tumor expression in BLCA. The BLCA box plot shows higher CCNJP2 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .024).
This table shows molecular features associated with CCNJP2 in patient tissues and cancer cell lines. In patient samples, CCNJP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
